28
October

08:00 AM BST

Drug Discovery Biology

Name: Medicinal Chemistry Strategy Meeting Europe 2026
Start: 2025-10-16T08:00
End: 2025-10-16T18:00
Location: Crowne Plaza, London Docklands

&

Medicinal Chemistry

Strategy Meeting Europe 2026

Reinvigorating Productivity in Pharma & Biotech R&D Through Advanced Technologies and Innovative Techniques that Interrogate Activity and Mechanisms

Crowne Plaza London Docklands

Our Event Starts In

–
days

–
hours

–
minutes

–
seconds

A MEETING EXPERIENCE UNLIKE ANY OTHER

Fresh Drug Discovery Biology & Medicinal Chemistry Insights

Tired of the same conference experience? Real discussions and genuine networking are often promised, but not always delivered. Proventa International’s R&D Strategy Meetings are designed to avoid the pitfalls of a typical conference, by providing the right environment to make those important connections through interactive roundtable discussions, exclusive networking and keynote panel debates. Join Medicinal Chemistry professionals from across Europe, to discover new insights and take your company’s mission to the next level.

What makes our strategy meetings unique?

Roundtable Discussions

Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.

Unrivalled Networking

With senior delegation from big pharma and innovative biotech from across Europe, you can network with peers from different locations, all in one place.

Personalised Agenda

Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.

Solutions to your Problems

We've partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.

Industry Researched Topics

We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.

Senior Decision Makers

The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.

Our Past Facilitators

Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at our Medicinal Chemistry strategy meeting.

Alessandro Mazzacani

Director of Chemistry and IP Sitryx

Chris Luckhurst

Head of Chemistry ThirtyFiveBio

Daniel Gironés

Managing Director Sapiens Natura Pharma

Elisabetta Chiarparin

Former SVP, Head of Discovery & Development Technologies Merck

Guido Koch

Chief Executive Officer Amphilix

Guido Koch is a board member of SynpleChem and co-founder and CEO of <a href="https://www.amphilix.com/">Amphilx</a>. From 2018 to 2020, Guido was the COO of Topadur Pharma and before a Director in Global Discovery Chemistry at Novartis.
During his career in drug discovery and development, Guido has lead projects in different phases from target identification to early clinical stage including multiple kinase inhibitors. Highlights from >20 years of experience in pharmaceutical industry include significant contributions to one marketed product and 8 clinical candidates.
Guido has built a strong network with academia and the CRO community, which allows him to support research programs by external knowledge, new technology and resources. His research has culminated in >45 scientific publications and 10 patent applications.
Educated at ETH Zürich, he received his Diploma in Chemistry and Biochemistry in 1991, followed from a PhD from the University of Basel. After a postdoc at Caltech, he joined Novartis in 1997.

Ismail Ijjaali, Ph.D

Director, EMEAI Field Application Scientist Team Revvity Signals

Markus Queisser

Scientific Director GSK

Matthew Fyfe

Chief Scientific Officer Outrun Tx

May Rezai

Chief Operations Officer MirZyme Therapeutics

Nicolas Triballeau, Ph.D

Director, Drug Discovery Chemistry Revvity Signals

Stephen Harrison

Former CSO Nucleome Therapeutics

Steven Zimmer

CEO Dark Matter Therapeutics

First name	Last name	Job title	Company name	Photo URL	Bio Position
Alessandro	Mazzacani	Director of Chemistry and IP	Sitryx	https://proventainternational.com/wp-content/uploads/2025/09/Alessandro-Mazzacani.jpg
Chris	Luckhurst	Head of Chemistry	ThirtyFiveBio	https://proventainternational.com/wp-content/uploads/2025/09/Chris-Luckhurst.jpg
Daniel	Gironés	Managing Director	Sapiens Natura Pharma	https://proventainternational.com/wp-content/uploads/2022/08/Daniel-Girones-1.jpg
Elisabetta	Chiarparin	Former SVP, Head of Discovery & Development Technologies	Merck	https://proventainternational.com/wp-content/uploads/2024/07/Elisabetta-Chiarparin.jpg
Guido	Koch	Chief Executive Officer	Amphilix	https://proventainternational.com/wp-content/uploads/2020/09/Guido-Koch.jpg	Guido Koch is a board member of SynpleChem and co-founder and CEO of Amphilx. From 2018 to 2020, Guido was the COO of Topadur Pharma and before a Director in Global Discovery Chemistry at Novartis. During his career in drug discovery and development, Guido has lead projects in different phases from target identification to early clinical stage including multiple kinase inhibitors. Highlights from >20 years of experience in pharmaceutical industry include significant contributions to one marketed product and 8 clinical candidates. Guido has built a strong network with academia and the CRO community, which allows him to support research programs by external knowledge, new technology and resources. His research has culminated in >45 scientific publications and 10 patent applications. Educated at ETH Zürich, he received his Diploma in Chemistry and Biochemistry in 1991, followed from a PhD from the University of Basel. After a postdoc at Caltech, he joined Novartis in 1997.
Ismail	Ijjaali, Ph.D	Director, EMEAI Field Application Scientist Team	Revvity Signals	https://proventainternational.com/wp-content/uploads/2020/10/Screenshot-2020-10-23-at-12.39.27-PM-e1603456923316.png	Ismail Ijjaali received his Ph.D. in chemistry from Henri-Poincaré University, Nancy, France. After his post-doctoral fellowship at Northwestern University Chicago and a diploma in Computational Chemistry, Ismail spent 8 years at Aureus Sciences (now part of Elsevier) where he was involved in consulting activities for their chemical/biological knowledge databases and managing several funded European projects in drug discovery. Ismail joined Revvity in 2012 as part of our Regional Marketing team working on Chemistry Enterprise solutions and Analytics. Currently Ismail was held the position as Director of the EMEAI Field Application Scientist team at Revvity Signals.
Markus	Queisser	Scientific Director	GSK	https://proventainternational.com/wp-content/uploads/2024/07/Markus-Queisser.jpg
Matthew	Fyfe	Chief Scientific Officer	Outrun Tx	https://proventainternational.com/wp-content/uploads/2020/04/Matthew-Fyfe-1.jpg
May	Rezai	Chief Operations Officer	MirZyme Therapeutics	https://proventainternational.com/wp-content/uploads/2025/07/May-Rezai.jpg
Nicolas	Triballeau, Ph.D	Director, Drug Discovery Chemistry	Revvity Signals	https://proventainternational.com/wp-content/uploads/2025/03/Nicolas-Triballeau.jpg	Nicolas Triballeau is the Drug Discovery Chemistry Lead at Revvity Signals. With 17 years of experience in drug discovery, he has not only provided direct project support and led teams but has also played a significant role in establishing scientific standards and ontologies. Nicolas holds a master’s degree in chemical engineering with a specialization in organic chemistry, a Pharm.D. and a Ph.D. in Drug Design from the University of Paris.
Stephen	Harrison	Former CSO	Nucleome Therapeutics	https://proventainternational.com/wp-content/uploads/2024/09/Stephen-Harrison.jpg
Steven	Zimmer	CEO	Dark Matter Therapeutics	https://proventainternational.com/wp-content/uploads/2020/03/Steven-Zimmer.jpg	Topic: Stratgic partnership of AI startup and Pharma (9:00am – 10:00am)

Alessandro Mazzacani, Chris Luckhurst, Daniel Gironés, Elisabetta Chiarparin, Guido Koch, Ismail Ijjaali, Ph.D, Markus Queisser, Matthew Fyfe, May Rezai, Nicolas Triballeau, Ph.D, Stephen Harrison, Steven Zimmer

Our Past Agenda

See Which Topics Are Discussed at the Strategy Meeting

08:30 - 09:00

AI in drug discovery: An opportunity to pivot away from target-centric drug discovery?

PRESENTER: Steven Zimmer, CEO, Dark Matter Therapeutics

09:00 - 10:00

Roundtable Tracks

Chemical Biology, Targeted Protein Degradation & Undruggables
Strategies for Targeted Protein Degradation: A Dive into PROTACs, Molecular Glues, and the Undruggable Proteome

-Daniel Gironés
Managing Director
Sapiens Natura Pharma

Target Identification/Lead Optimization
Fragment Based Drug Discovery (Topic TBC)

-Stephen Harrison
Former CSO
Nucleome Therapeutics

Integrated Drug Discovery
From Hit to Lead: Accelerating Drug Discovery Through Cutting-Edge Chemistry and Innovative Screening Strategies (Topic TBC)

-May Rezai
Chief Operations Officer
MirZyme Therapeutics

Private Equity, Venture Capital & Strategic Partnerships
How does biotech and pharma react to the geopolitical changes and how does this affect collaboration and partnering strategies

-Guido Koch
Chief Executive Officer
Amphilix

11:10 - 12:10

Roundtable Tracks

Chemical Biology, Targeted Protein Degradation & Undruggables
Navigating Complexity in Emerging Modalities: Transforming PROTAC, Peptide, Oligonucleotide, and ADC Drug Discovery

-Nicolas Triballeau, Ph.D
Director, Drug Discovery Chemistry
Revvity Signals

Revvity Signals

Target Identification/Lead Optimization
Fragment Based Drug Discovery in the Spotlight: Emerging Trends in Hit Identification and Lead Optimization

Sponsor

Integrated Drug Discovery
The Data Integration Crisis in Drug Discovery

-Ismail Ijjaali, Ph.D
Director, EMEAI Field Application Scientist Team
Revvity Signals

Revvity Signals

Private Equity, Venture Capital & Strategic Partnerships
How Strategic Partnerships Revolutionize Pharma R&D

Sponsor

12:15 - 13:15

Roundtable Tracks

Chemical Biology, Targeted Protein Degradation & Undruggables
From Discovery to Application: Challenges in Using Chemical Probes for Degrader Development

-Markus Queisser
Scientific Director
GSK

Target Identification/Lead Optimization
Drugging Protein:Protein Interactions: Best practices in hit identification and lead optimization of undruggable complexes (Topic TBC)

-Chris Luckhurst
Head of Chemistry
ThirtyFiveBio

Integrated Drug Discovery
The Next Frontier in Therapeutic RNA: Exploring Computational and AI-Driven Approaches for Target Identification, mRNA Synthesis, and Small Molecule Integration (Topic TBC)

-Zayd Rasool
Board Member
Kingston University

Private Equity, Venture Capital & Strategic Partnerships
Redefining Drug Discovery Success Through Strategic and Venture Partnerships: Catalyzing Innovation Across Pharma R&D

-Matthew Fyfe
Chief Scientific Officer
Outrun Tx

14:40 - 15:10

Augmented Discovery: How Revvity Signals AI/ML Amplifies Scientific Discovery

PRESENTER: PRESENTER: Nicolas Triballeau, Ph.D., Director – Drug Discovery Chemistry, Revvity Signals

15:10 - 16:10

Roundtable Tracks

Chemical Biology, Targeted Protein Degradation & Undruggables
Emerging “Undruggable” Targets in Targeted Protein Degradation

-Markus Queisser
Scientific Director
GSK

Target Identification/Lead Optimization
AI-Driven Drug Discovery: Transforming Hit Identification and Lead Optimization (Topic TBC)

-Alessandro Mazzacani
Director of Chemistry and IP
Sitryx

Integrated Drug Discovery
Blood-Brain Barrier Penetration in Drug Discovery - Challenges, Innovations, and Future Directions (Topic TBC)

-Chandan Seth Nanda
Entrepreneur in Residence
Antler

Private Equity, Venture Capital & Strategic Partnerships
The Role of Venture Partnerships in Drug Discovery

-Lincoln Tsang
Partner & Head of European Life Sciences Practice
Ropes & Gray LLP

16:30 - 17:00

Fueling the Future: How Venture Capital is Reshaping Drug Discovery Innovation

PRESENTER: Melina Hoffmann, Associate, Syncona Investment Management Limited

Press play to hear what your colleagues had to say...

Hotel & Venue

Crowne Plaza London Docklands

Our hotel is a haven from the hustle & bustle of London life - you’ll find peace & tranquility in modern surroundings. We’re close to The O2 Arena, ExCeL Exhibition Centre & Canary Wharf.

Hotel Details Map & Directions Parking

Quick Links

Want to find out more?

Find out more details about our Strategy Meetings and other news and events.

Here To Help

Want to know more? Interested in sponsoring the event? Need help registering your team? Just get in touch and a member of the team will be happy to help.

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

R&D Europe

Medicinal Chemistry Strategy Meeting Europe 2024

&

Strategy Meeting Europe 2026

<img class="lazy" decoding="async" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >Crowne Plaza London Docklands

Fresh Drug Discovery Biology & Medicinal Chemistry Insights

What makes our strategy meetings unique?

Roundtable Discussions

Unrivalled Networking

Personalised Agenda

Solutions to your Problems

Industry Researched Topics

Senior Decision Makers

Our Past Facilitators

Alessandro Mazzacani

Chris Luckhurst

Daniel Gironés

Elisabetta Chiarparin

Guido Koch

Ismail Ijjaali, Ph.D

Markus Queisser

Matthew Fyfe

May Rezai

Nicolas Triballeau, Ph.D

Stephen Harrison

Steven Zimmer

Our Past Agenda

See Which Topics Are Discussed at the Strategy Meeting

BREAKFAST & REGISTRATION

Opening Keynote

AI in drug discovery: An opportunity to pivot away from target-centric drug discovery?

Roundtable ( Pharma/Biotech )

Roundtable Tracks

Refreshment Break

Networking/1-1 Meetings

Roundtable ( Solutions )

Roundtable Tracks

Revvity Signals

Sponsor

Revvity Signals

Sponsor

Rountable Discussion ( Pharma/Biotech )

Roundtable Tracks

Networking Lunch

Networking/1-1 Meetings

Afternoon Keynote Presentation

Augmented Discovery: How Revvity Signals AI/ML Amplifies Scientific Discovery

Roundtable ( Pharma/Biotech )

Roundtable Tracks

Afternoon Refreshment Break

Panel Discussion

Fueling the Future: How Venture Capital is Reshaping Drug Discovery Innovation

Drinks & Canapes Reception

See the full agenda and facilitator line-up

Reasons To Attend Our Strategy Meetings

Fully Interactive Format

Senior Decision Makers

Personalised Agendas

Private and Intimate Networking

Our Past Sponsors

Lead Sponsor

Partnering Sponsors

Key Opinion Leader

Media Partner

Become an official strategy meeting partner

Explore Highlight From The Past Events

Press play to hear what your colleagues had to say...

Hotel & Venue

Crowne Plaza London Docklands

Want to find out more?

Here To Help

Select days you wish to attend You can add multiple days

Daily Delegate Rate includes:

VAT Excluded

Crowne Plaza London Docklands